Catalyst
Slingshot members are tracking this event:
CymaBay (CBAY) to Present Two Phase 2 Studies of Arhalofenate for Gout Patients at the American College of Rheumatology Annual Meeting
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 07, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Gout, Phase 2, Arhalofenate
